eltp stock price premarket

by Lia Hintz Published 3 years ago Updated 2 years ago

What is the elite Pharmaceuticals stock forecast for 2023?

The Elite Pharmaceuticals stock forecast is 0.087891805878012 USD for 2023 March 21, Tuesday; and 0.421 USD for 2027 March 21, Sunday. Elite Pharmaceuticals stock forecast, ELTP price prediction: Buy or sell Elite Pharmaceuticals, Inc shares?

What does eltp stand for?

NORTHVALE, NJ / ACCESSWIRE / August 9, 2019 / Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, announced results for the first quarter of fiscal year 2020 ended June 30, 2019 (“First Quarter”).

What time does elite pharmaceuticals (eltp) release earnings?

NEW YORK, NY / ACCESSWIRE / February 17, 2021 / Elite Pharmaceuticals, Inc. (OTCQB:ELTP) will be discussing their earnings results in their 2021 Third Quarter Earnings call to be held on February 17, 2021 at 11:30 AM Eastern Time.

Is elite Pharmaceuticals Inc (ELPT) a buy or sell?

The Elite Pharmaceuticals Inc stock holds a buy signal from the short-term moving average; at the same time, however, the long-term average holds a general sell signal. Since the longterm average is above the short-term average there is a general sell signal in the stock giving a more negative forecast for the stock.

Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year Ended December 31, 2021 and Provides Conference Call Information

Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2022 Financial Results on February 15, 2022

Conference Call Scheduled for Tuesday, February 15 at 11:30 AM ESTNORTHVALE, NJ / ACCESSWIRE / February 14, 2022 / Elite Pharmaceuticals, Inc.

Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year Ended September 30, 2021 and Provides Conference Call Information

Financials for Third Quarter Fiscal Year 2022 Ended December 31, 2021 will be released February 14, 2022NORTHVALE, NJ / ACCESSWIRE / February 9, 2022 / Elite Pharmaceuticals, Inc.

Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2022 Financial Results on November 16, 2021

Conference Call Scheduled for Tuesday, November 16th at 11:30 AM ESTNORTHVALE, NJ / ACCESSWIRE / November 15, 2021 / Elite Pharmaceuticals, Inc.

Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2022 Ended June 30, 2021 and Provides Conference Call Information

Financials for Second Quarter Fiscal Year 2022 Ended September 30, 2021 will be released November 15, 2021NORTHVALE, NJ / ACCESSWIRE / November 9, 2021 / Elite Pharmaceuticals, Inc.

Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter 2022 Financial Results on August 17, 2021

Conference Call Scheduled for Tuesday, August 17 at 11:30 AM EDTNORTHVALE, NJ / ACCESSWIRE / August 16, 2021 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company”) (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, announced results for the first quarter of fiscal year 2022 ended June 30, 2021 ("First Quarter").

Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2021 and Provides Conference Call Information

Financials for First Quarter Fiscal Year 2022 Ended June 30, 2021 will be released August 16, 2021NORTHVALE, NJ / ACCESSWIRE / August 10, 2021 / Elite Pharmaceuticals, Inc.

Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year Ended December 31, 2021 an..

Conference Call Scheduled for Tuesday, June 15 at 11:30 AM EDTNORTHVALE, NJ / ACCESSWIRE / June 14, 2021 / Elite Pharmaceuticals, Inc. ('Elite' or the "Company') (OTCBB:ELTP), a specialty pharmaceutical company developing niche generic products, announced results for the fiscal year ended March 31, 2021 ("Fiscal 2021").

Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2022 Financ..

Conference Call Scheduled for Tuesday, February 15 at 11:30 AM EST NORTHVALE, NJ / ACCESSWIRE / February 14, 2022 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharma...

Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year Ended September 30, 2021 ..

Financials for Third Quarter Fiscal Year 2022 Ended December 31, 2021 will be released February 14, 2022 NORTHVALE, NJ / ACCESSWIRE / February 9, 2022 / Elite Pharmaceuticals, Inc. ("Elite" or the "Comp...

Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2022 Finan..

Conference Call Scheduled for Tuesday, November 16th at 11:30 AM EST NORTHVALE, NJ / ACCESSWIRE / November 15, 2021 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty phar...

Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2022 Ended June 30, 2021 a..

Financials for Second Quarter Fiscal Year 2022 Ended September 30, 2021 will be released November 15, 2021 NORTHVALE, NJ / ACCESSWIRE / November 9, 2021 / Elite Pharmaceuticals, Inc. ("Elite" or the "Co...

Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2021 and Provides Conferenc..

Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Year-End Financial Result..

Signals & Forecast

Financials for Fiscal Year Ended March 31, 2021 will be released June 14, 2021 NORTHVALE, NJ / ACCESSWIRE / June 8, 2021 / Elite Pharmaceuticals, Inc. ('Elite' or the "Company') (OTCBB:ELTP), a specialt...

Support, Risk & Stop-loss

Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Elite Pharmaceuticals Inc has increased volume and follows the last lift in the price. This is considered to be a technical positive sign as volume should follow the price-formation.

Is Elite Pharmaceuticals Inc stock A Buy?

On the downside, the stock finds support just below today's level from accumulated volume at $0.0360 and $0.0350. There is natural risk involved when a stock is testing a support level, since if this is broken, the stock then may fall to the next support level.

Insiders are very positive buying more shares than they are selling in Elite Pharmaceuticals Inc

The Elite Pharmaceuticals Inc stock holds several negative signals and despite the positive trend, we believe Elite Pharmaceuticals Inc will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock.

About Elite Pharmaceuticals Inc

In the last 100 trades there were 506.04 million shares bought and 462.7 million shares sold. The last trade was done 238 days ago by Dash Barry H who bough 295.57 thousand shares. The large amount of stocks bought compared to stocks sold indicate that the insiders believe there is a potential good upside.

Golden Star Signal

Elite Pharmaceuticals, Inc. engages in the research, development, manufacture, and licensing of proprietary orally administered controlled-release drug delivery systems and products. The company operates in two segments, Abbreviated New Drug Applications for Generic Products and New Drug Applications for Branded Products.

Top Fintech Company

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Stock FAQs